Lobular Breast Carcinoma

7

Review clinical trials related to Lobular Breast Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

Participants needed: 12
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University of California, San FranciscoUpdated: Jul 2, 2026Locations: 4Duration: 10 Years
Eligibility criteria

Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer... [+3]

Stage I-III breast cancer. [+2]

Status: Recruiting

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer

Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.

Participants needed: 119
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Università Vita-Salute San RaffaeleUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

Female patients, age>= 18 yrs, diagnosed with primary or advanced breast cancer [+3]

ER-negative tumors [+6]

Status: Recruiting

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).

Participants needed: 176
Trial details
Phase: Phase 2Age: 50+Biological sex: FemaleType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Jun 4, 2026Locations: 7
Eligibility criteria

Written informed consent by participant or legally authorized representative [+3]

Patients with prior ipsilateral breast cancer. [+4]

Status: Recruiting

Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer

The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

Participants needed: 250
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Istituto Oncologico Veneto IRCCSUpdated: May 29, 2026Locations: 1
Eligibility criteria

Female or male patients aged ≥18 years. [+6]

Pure ductal carcinoma without lobular invasive component. [+4]

Status: Recruiting

Biomarkers to Detect Endocrine Therapy Resistance

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

Participants needed: 8
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

Willing to provide informed consent [+6]

Patients with active brain metastases [+7]

Status: Recruiting

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

Participants needed: 26
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Mar 30, 2026Locations: 7
Eligibility criteria

Patients with biopsy confirmed advanced/metastatic solid tumors of the following... [+2]

Patients who are pregnant or breastfeeding [+7]

Status: Recruiting

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Feb 27, 2026Locations: 7
Eligibility criteria

Adult patient > 18 years old [+6]

Low ER expression defined as ER <10% of tumor cells by IHC [+3]